ОЦЕНКА ВЛИЯНИЯ КОМБИНАЦИИ ОФТАЛЬМОЛОГИЧЕСКИХ ПРЕПАРАТОВ НА КУЛЬТУРУ КЛЕТОК КОНЪЮНКТИВЫ ЧЕЛОВЕКА (CHANG CONJUNCTIVA)

Objective . Investigation of the cytological and immunological effects, caused by the simultaneous exposure of normal Chanq conjunctiva cells to ophthalmic drugs Broxinac® and Ophthalmoferon®, in order to improve the evaluation techniques of ophthalmic drugs combinations in vitro. Material and methods. A transplantable culture of normal Chang conjunctiva cells, clone 1-5 C-4, was used. The drugs Broksinak® and Oftalmoferon® were quantified by their effect on cell viability using the MTT method. The change in cell morphology during the cultivation process was studied by intravital visual observation. The effect of the combination of drugs on the functional activity of conjunctival cells was assessed by production of cytokines at the level of their in vitro transcription. Results. The investigated drugs (dilutions 1/512-1/2048 Broksinak® and 1/32-1/2048 Oftalmoferon®) were incubated with human Chang conjunctiva cells for 48 hours and did not cause an inhibition of growth activity or viability, and did not change the morphology of the cells, and the test sample was not different from the state of the control cells. Cytokine production by cells of the conjunctiva when exposed to Broksinak® alone stimulated secretion of antiviral IFN-α and IFN-λ and inhibition of production of proinflammatory IFN-γ, IL-2, IL-8, IL-12. Ophthalmoferon stimulated the production of IFN-α and VEGF R1. The production of RNA IFN-α, IFN-λ2, IL-2, IL-12 was observed in drug’s combination. С onclusions. The combined use of Broksinak® and Oftalmoferon® on human Chang conjunctiva cells results in the formation of an adequate antiviral and anti-inflammatory cytokine response: i.e. increase of IFNalpha production, IFN-lambda, IL-2 and IL-12.